Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at financialmarketpress.com, will continue to monitor these healthtech companies to see if the momentum continues. FinancialMarketPress.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..
Recent BIIB Stock Price: $305.17
Summary: Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Paul Matteis analyst at Stifel Nicolaus reiterates coverage on Biogen (BIIB) stock in the energy sector with a Buy rating and has set BIIB's stock price target at n/a.
TipRanks.com reports that Biogen currently has 26 analysts offering 12-month price targets on BIIB and the consensus is a Moderate Buy rating with an average stock price target of $310.58. The most recent BIIB stock price we have is $305.17 and we are not making any BIIB forecasts at this time.
In addition, TradingView issued a n/a (possibly response change) rating for BIIB over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on BIIB. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on BIIB, please click here >>
Arrowhead Pharmaceuticals, ARWR
Recent ARWR Stock Price: $32.2
Summary: Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.
Mayank Mamtani analyst at B.Riley Financial reiterates coverage on Arrowhead Pharmaceuticals (ARWR) stock in the energy sector with a Buy rating and has set ARWR's stock price target at $ 59.
TipRanks.com reports that Arrowhead Pharmaceuticals currently has 8 analysts offering 12-month price targets on ARWR and the consensus is a Strong Buy rating with an average stock price target of $61.38. The most recent ARWR stock price we have is $32.2 and we are not making any ARWR forecasts at this time.
In addition, TradingView issued a n/a (possibly response change) rating for ARWR over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ARWR. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ARWR, please click here >>
Cincor Pharma, CINC
Recent CINC Stock Price: $11.8
Summary: CinCor Pharma Inc. is a clinical-stage biopharmaceutical company. It focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CinCor Pharma Inc. is based in BOSTON.
Dennis Ding analyst at Jefferies reiterates coverage on Cincor Pharma (CINC) stock in the energy sector with a Buy rating and has set CINC's stock price target at $ 50.
TipRanks.com reports that Cincor Pharma currently has 6 analysts offering 12-month price targets on CINC and the consensus is a Moderate Buy rating with an average stock price target of $43.00. The most recent CINC stock price we have is $11.8 and we are not making any CINC forecasts at this time.
In addition, TradingView issued a n/a (possibly response change) rating for CINC over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on CINC. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on CINC, please click here >>
Fisher & Paykel Healthcare Corporation Limited, FSPKF
Recent FSPKF Stock Price: $14.9
Summary: Fisher & Paykel Healthcare Corp Ltd is a designer, manufacturer and marketer of medical device products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. The Company operates in four segments: New Zealand. Includes all activities controlled by entities or employees based in New Zealand, principally research and development, manufacturing, marketing, sales and distribution and administration. The research and development activity relates to New Zealand. The manufacturing activity principally relates to New Zealand, however the Mexico manufacturing activity is also included in this segment as the Mexico facility is managed by New Zealand-based employees. The sales and distribution activity principally relates to New Zealand, Latin America, Africa, the Middle East and other countries in Asia. Also included are sales made to countries within Europe and Asia-Pacific where the management of the sale is from New Zealand; North America. Includes all activities controlled by entities or employees based in the United States of America and Canada, principally sales, distribution and administration activities; Europe. Includes all activities controlled by entities or employees based in the United Kingdom, France, Germany, Sweden and Turkey, principally sales, distribution and administration activities. These sales and distribution hubs also distribute product into neighboring European countries; and Asia-Pacific. Includes all activities controlled by entities or employees based in Australia, Japan, India, China, South Korea, Taiwan and Hong Kong, principally sales, distribution and administration activities.
Gretel Janu analyst at Credit Suisse reiterates coverage on Fisher & Paykel Healthcare Corporation Limited (FSPKF) stock in the energy sector with a Hold rating and has set FSPKF's stock price target at $ 14.39.
TipRanks.com reports that Fisher & Paykel Healthcare Corporation Limited currently has 6 analysts offering 12-month price targets on FSPKF and the consensus is a Hold rating with an average stock price target of $14.75. The most recent FSPKF stock price we have is $14.9 and we are not making any FSPKF forecasts at this time.
In addition, TradingView issued a n/a (possibly response change) rating for FSPKF over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on FSPKF. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on FSPKF, please click here >>
Horizon Therapeutics, HZNP
Recent HZNP Stock Price: $100.29
Summary: Horizon Therapeutics plc is a biopharmaceutical focused on making drugs in arthritis, pain, inflammatory and orphan diseases areas.
Douglas Tsao analyst at H.C. Wainwright reiterates coverage on Horizon Therapeutics (HZNP) stock in the energy sector with a Hold rating and has set HZNP's stock price target at n/a.
TipRanks.com reports that Horizon Therapeutics currently has 12 analysts offering 12-month price targets on HZNP and the consensus is a Strong Buy rating with an average stock price target of $103.45. The most recent HZNP stock price we have is $100.29 and we are not making any HZNP forecasts at this time.
In addition, TradingView issued a n/a (possibly response change) rating for HZNP over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on HZNP. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on HZNP, please click here >>
X4 Pharmaceuticals, XFOR
Recent XFOR Stock Price: $1.5
Summary: X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States.
Mayank Mamtani analyst at B.Riley Financial reiterates coverage on X4 Pharmaceuticals (XFOR) stock in the energy sector with a Buy rating and has set XFOR's stock price target at $ 7.
TipRanks.com reports that X4 Pharmaceuticals currently has 4 analysts offering 12-month price targets on XFOR and the consensus is a Strong Buy rating with an average stock price target of $6.13. The most recent XFOR stock price we have is $1.5 and we are not making any XFOR forecasts at this time.
In addition, TradingView issued a n/a (possibly response change) rating for XFOR over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on XFOR. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on XFOR, please click here >>
The editors at financialmarketpress.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
FinancialMarketPress.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinancialMarketPress.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================